Peptide Therapy
Why the 503A vs. 503B Distinction Is the Only Regulatory Story That Matters Right Now
503A vs 503B compounding: What patients need to know about peptide sourcing, sterility standards, and safe access
Compounding
Peptides
They Announced 19 Peptides on Joe Rogan. Nothing's Changed.
RFK Jr. announced 19 peptides on Joe Rogan, but FDA reclassification has not happened yet. Here is the actual GLP-1 and non-GLP-1 peptide timeline.
GLP-1
GLP-1s Are Not Being Banned. The Shortcut Is Being Closed.
GLP-1s are not being banned. The FDA is rolling back the 503B bulk-manufacturing shortcut, and patients need more than medication in the mail.
MOTS-c
MOTS-c and the July 23 Decision That Could End Compounding Access
MOTS-c is the only peptide with two human trials. One proved it worked — then the company dissolved. The second is running. July 23, the FDA decides compounding access.